The article entitled “Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission” was published Februin ' Advances in the Treatment of Ovarian Cancer,” a special issue of the journal Cancers.īroader than expected GPS immunologic responses encompassed both T-cells and antibodies. We are encouraged by the growing collection of evidence that confirms our belief in GPS’s potential to provide disease control not only for ovarian cancer, but also for other WT1-expressing tumors, especially in combination with checkpoint blockade.” Clinical research is crucial in identifying novel alternative therapies, including immunotherapies. “Standard chemotherapy regimens have limited efficacy, as evidenced by the fact that almost half of the population of patients achieving macroscopic remission with salvage regimens do experience disease relapse within a year. “A significant unmet medical need exists for patients with advanced epithelial ovarian cancer following initial surgery and chemotherapy, with over 70% experiencing recurrence after they achieve clinical remission,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced that the previously reported results from the final analysis of a Phase 1 clinical trial of the combination of galinpepimut-S (GPS) with the anti-PD-1 antibody nivolumab (Opdivo ®) in patients with relapsed WT1-expressing ovarian cancers (NCT02737787) have been published in the peer-reviewed journal Cancers.

NEW YORK, Ma(GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc.

Smart endpoint checkpoint